Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies

Abstract

The purpose of this study was to determine the maximum tolerated dose of carboplatin administered with 500 mg/m2 thiotepa and 100 mg/m2melphalan followed by autologous peripheral blood stem cell (PBSC) infusion in patients with refractory malignancies. Twenty-eight patients with refractory malignancies received high-dose thiotepa (500 mg/m2, melphalan (100 mg/m2) and escalating doses of carboplatin 900–1500 mg/m2) followed by infusion of cryopreserved autologous PBSCs. The maximum tolerated doses were determined to be 500 mg/m2 thiotepa, 100 mg/m2 melphalan and 1350 mg/m2 carboplatin. Two consecutive patients receiving 1500 mg/m2 carboplatin experienced grade 3 mucositis and colitis. Ten patients were enrolled at the maximum tolerated dose and none had grade 3–4 regimen-related toxicity and mortality. All patients at this level experienced grade 1–2 mucositis, 90% grade 1–2 gastrointestinal toxicity, 30% grade 1–2 cardiac and renal toxicity, and 10% experienced grade 1 hepatic toxicity. The median time to achieve a granulocyte count of 0.5 × 109/l was 9 days (range 7–12 days) and platelet count of 20 × 109/l was 10 days (range 7–15 days). Of eight patients with stage IV refractory breast cancer, even were evaluable for response, one patient on day 75 will be evaluated soon. Five of seven (71.5%) evaluable patients achieved a complete remission (CR) and two had no response. Of seven patients with non-Hodgkin's lymphoma (n = 4) or Hodgkin's disease (n = 3), five achieved a CR (71.5%). Thiotepa, melphalan and carboplatin can be administered in high doses with tolerable mucositis as the major side-effect. This combination has significant activity in patients with breast cancer, and phase II studies in patients with breast cancer and other chemotherapy-sensitive malignancies are warranted. Bone Marrow Transplantation (2000) 25 , 697–703.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle J Clin Oncol 1990 8: 638–647

    Article  CAS  Google Scholar 

  2. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation (ABMT) for acute leukemia in remission: an analysis of 1322 cases Bone Marrow Transplant 1989 4: (Suppl.2) 3–5

    Google Scholar 

  3. Eder JP, Elias A, Shea TC et al. A phase I–II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients J Clin Oncol 1990 8: 1239–1245

    Article  CAS  Google Scholar 

  4. Moormeier JA, Williams SF, Kaminer LS et al. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies J Natl Cancer Inst 1990 82: 29–34

    Article  CAS  Google Scholar 

  5. Eder JP, Antman K, Elias A et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors J Natl Cancer Inst 1988 80: 1221–1226

    Article  CAS  Google Scholar 

  6. Williams SF, Bitran JD, Kaminer L et al. A phase I–II study of bialkylator chemotherapy, high-dose thiotepa and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer J Clin Oncol 1987 5: 260–265

    Article  CAS  Google Scholar 

  7. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer J Clin Oncol 1986 4: 1592–1597

    Article  CAS  Google Scholar 

  8. Stiff PJ, McKenzie RS, Albert DS et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma J Clin Oncol 1994 12: 176–183

    Article  CAS  Google Scholar 

  9. Antman K, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879

    Article  CAS  Google Scholar 

  10. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan, and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer Bone Marrow Transplant 1996 17: 769–774

    CAS  PubMed  Google Scholar 

  11. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 1988 6: 1368–1376

    Article  CAS  Google Scholar 

  12. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer J Clin Oncol 1989 7: 1824–1830

    Article  CAS  Google Scholar 

  13. Holmberg LA, Demirer T, Rowley S et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III–IV ovarian cancer Bone Marrow Transplant 1998 22: 651–659

    Article  CAS  Google Scholar 

  14. Ozols RF, Ihde DC, Linehan M et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumors J Clin Oncol 1988 6: 1031–1040

    Article  CAS  Google Scholar 

  15. Lazarus HM, Reed MD, Spitzer TR et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer Cancer Treat Rep 1987 71: 689–695

    CAS  PubMed  Google Scholar 

  16. Wolff SN, Herzig RH, Fay JW et al. High-dose N, N′, N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies Semin Oncol 1990 17: 2–6

    CAS  PubMed  Google Scholar 

  17. Lazarus HM, Herzig RH, Graham-Pole J et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer J Clin Oncol 1983 1: 359–367

    Article  CAS  Google Scholar 

  18. Demirer T, Petersen FB, Bensinger WI et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte-colony stimulating factor in patients with acute myelogenous leukemia Bone Marrow Transplant 1996 18: 29–34

    CAS  PubMed  Google Scholar 

  19. Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan J Clin Oncol 1988 6: 1768–1782

    Article  CAS  Google Scholar 

  20. Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide Ann NY Acad Sci 1958 68: 937–966

    Article  CAS  Google Scholar 

  21. Farber S, Appleton R, Downing V et al. Clinical studies on the carcinolytic action of triethylenephosphoramide Cancer 1953 6: 135–141

    Article  Google Scholar 

  22. Lemaistre CF, Herzig GP, Herzig RH et al. High-dose thiotepa and autologous bone marrow rescue for the treatment of breast cancer Breast Cancer Res Treat 1987 10: 89–94

    Google Scholar 

  23. Maranichi D, Piana L, Blaise D et al. Phase I–II studies of high-dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplant. In: Dicke K, Spitzer TR, Jagannath S (eds) ABMT: Proceedings of the 3rd international symposium University of Texas MD Anderson Hospital: Houston, TX 1987 475–480

    Google Scholar 

  24. Corringham R, Gilmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors Cancer 1983 52: 1783–1787

    Article  CAS  Google Scholar 

  25. Bateman JC . Chemotherapy of solid tumors with triethylene thiophosphamide New Engl J Med 1955 252: 879–887

    Article  CAS  Google Scholar 

  26. Ultmann JE, Hyman GA, Crandall C et al. Triethylenephosphoramide (thiotepa) in the treatment of neoplastic disease Cancer 1957 10: 902–911

    Article  CAS  Google Scholar 

  27. Ozols RF, Behrens BC, Ostchega Y et al. High-dose cisplatin and high-dose carboplatin in refractory ovarian cancer Cancer Treatment Rev 1985 12: 59–62

    Article  CAS  Google Scholar 

  28. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support J Clin Oncol 1989 7: 651–655

    Article  CAS  Google Scholar 

  29. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 1992 10: 102–110

    Article  CAS  Google Scholar 

  30. Holland K, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care J Clin Oncol 1996 14: 1156–1164

    Article  CAS  Google Scholar 

  31. Ayash L, Elias A, Ibrahim J et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma J Clin Oncol 1998 16: 1000–1007

    Article  CAS  Google Scholar 

  32. Demirer T, Buckner CD, Bensinger WI et al. Peripheral blood stem cell (PBSC) collections after taxol, cyclophosphamide and recombinant human granulocyte-colony-stimulating factor (rhG-CSF) J Clin Oncol 1995 13: 1714–1719

    Article  CAS  Google Scholar 

  33. Demirer T, Buckner CD, Bensinger WI et al. Optimization of peripheral blood stem cell mobilization Stem Cells 1996 14: 106–116

    Article  CAS  Google Scholar 

  34. Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte-colony stimulating factor J Clin Oncol 1997 15: 684–690

    Article  CAS  Google Scholar 

  35. Demirer T, Bensinger WI, Buckner CD . Peripheral blood stem cell mobilization for high-dose chemotherapy J Hematother 1999 8: 103–113

    Article  CAS  Google Scholar 

  36. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients Transfusion 1997 37: 896–903

    Article  CAS  Google Scholar 

  37. Bensinger W, Singer J, Appelbaum FR et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte-stimulating factor Blood 1993 81: 3158–3163

    CAS  PubMed  Google Scholar 

  38. Thomas ED, Storb R . Technique for human marrow grafting Blood 1970 36: 507–515

    CAS  PubMed  Google Scholar 

  39. Buckner CD, Appelbaum FR, Thomas ED . Bone marrow and fetal liver. In: Karow AM Jr, Pegg DE (eds) Organ Preservation for Transplantation Marcel Dekker: New York 1981 pp355–375

    Google Scholar 

  40. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  Google Scholar 

  41. Hsi BP . The multiple sample up-and-down method in bioassay J Am Stat Assoc 1969 64: 147–162

    Article  Google Scholar 

  42. Frei E III, Canellos GP . Dose: a critical factor in cancer chemotherapy Am J Med 1986 69: 585–599

    Article  Google Scholar 

  43. Frei E III, Cucchi GA, Rosowsky A et al. Alkylating agents resistance: in vitro studies with human cell lines Proc Natl Acad Sci USA 1985 82: 2158–2162

    Article  Google Scholar 

  44. Frei E III, Teicher B, Cucchi GA et al. Resistance to alkylating agents: basic studies and therapeutic implications. In: Wooley P III, Tew K (eds) Mechanism of Drug Resistance in Neoplastic Cells Academic Press: New York 1988 pp69–87

    Chapter  Google Scholar 

  45. Hyrniuk WM . Relative dose intensity and the impact on design of clinical trials Semin Oncol 1987 14: 65–74

    Google Scholar 

  46. Broder LE, Tormey DC . Combination chemotherapy of carcinoma of the breast cancer Cancer Treat Rev 1974 1: 183–203

    Article  Google Scholar 

  47. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 1989 7: 1748

    Article  CAS  Google Scholar 

  48. Weaver CH, Greco FA, Hainsworth J et al. A phase I–II study of high-dose melphalan, mitoxantrone and carboplatin with PBSC support in patients with advanced ovarian or breast carcinoma Bone Marrow Transplant 1997 20: 847–853

    Article  CAS  Google Scholar 

  49. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan, and thiotepa with autologous stem cell support in patients with refractory malignancies Bone Marrow Transplant 1994 14: 813–819

    CAS  PubMed  Google Scholar 

  50. Srivastava A, Bradstock KF, Szer J et al. Busulfan and melphalan prior to autologous bone marrow transplantation Bone Marrow Transplant 1993 12: 323–329

    CAS  PubMed  Google Scholar 

  51. Schiffman K, Buckner CD, Maziarz R et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease Biol Blood Marrow Transplant 1997 3: 261–266

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demirer, T., lhan, O., Mandel, N. et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 25, 697–703 (2000). https://doi.org/10.1038/sj.bmt.1702239

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702239

Keywords

This article is cited by

Search

Quick links